Terms: = Sarcomas AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR
161 results:
1. A high-content screen of FDA approved drugs to enhance car T cell function: ingenol-3-angelate improves B7-H3-car T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation.
Lee HW; O'Reilly C; Beckett AN; Currier DG; Chen T; DeRenzo C
J Exp Clin Cancer Res; 2024 Apr; 43(1):97. PubMed ID: 38561833
[TBL] [Abstract] [Full Text] [Related]
2. Targeting osteosarcoma with canine B7-H3 car T cells and impact of CXCR2 Co-expression on functional activity.
Cao JW; Lake J; Impastato R; Chow L; Perez L; Chubb L; Kurihara J; Verneris MR; Dow S
Cancer Immunol Immunother; 2024 Mar; 73(5):77. PubMed ID: 38554158
[TBL] [Abstract] [Full Text] [Related]
3. Protocol for a mixed-methods study to develop and feasibility test a digital system for the capture of patient-reported outcomes (PROs) in patients receiving chimeric antigen receptor T-cell (car-T) therapies (the PRO-car-T study).
Hughes SE; McMullan C; Aiyegbusi OL; Shaw K; Kinsella F; Ferguson P; Khatsuria F; Burns D; Pyatt L; Ansell J; Chakera E; Richardson-Abraham J; Denniston AK; Davies EH; Craddock C; Calvert M
BMJ Open; 2024 Mar; 14(3):e085392. PubMed ID: 38553074
[TBL] [Abstract] [Full Text] [Related]
4. Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review).
Yu T; Jiang W; Wang Y; Zhou Y; Jiao J; Wu M
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38390935
[TBL] [Abstract] [Full Text] [Related]
5. Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus.
Uotani K; Tazawa H; Hasei J; Fujiwara T; Yoshida A; Yamakawa Y; Omori T; Sugiu K; Komatsubara T; Kondo H; Morita T; Kiyono M; Yokoo S; Hata T; Kunisada T; Takeda K; Urata Y; Fujiwara T; Ozaki T
PLoS One; 2024; 19(2):e0298292. PubMed ID: 38377118
[TBL] [Abstract] [Full Text] [Related]
6. A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [
Trautwein NF; Schwenck J; Seitz C; Seith F; Calderón E; von Beschwitz S; Singer S; Reischl G; Handgretinger R; Schäfer J; Lang P; Pichler BJ; Schulte JH; la Fougère C; Dittmann H
Theranostics; 2024; 14(3):1212-1223. PubMed ID: 38323317
[No Abstract] [Full Text] [Related]
7. Histiocytic sarcoma following car T-cell therapy: a case report.
An K; He Y; Tang Y; Gu X; Qian J; Li B
Int J Hematol; 2024 Mar; 119(3):338-341. PubMed ID: 38294639
[TBL] [Abstract] [Full Text] [Related]
8. Role of Immunotherapy in sarcomas.
Dalal S; Shan KS; Thaw Dar NN; Hussein A; Ergle A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279265
[TBL] [Abstract] [Full Text] [Related]
9. Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers.
Jin Y; Dunn C; Persiconi I; Sike A; Skorstad G; Beck C; Kyte JA
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203757
[TBL] [Abstract] [Full Text] [Related]
10. Current status and future challenges of car-T cell therapy for osteosarcoma.
Li S; Zhang H; Shang G
Front Immunol; 2023; 14():1290762. PubMed ID: 38187386
[TBL] [Abstract] [Full Text] [Related]
11. GD2-car car T cells in patients with osteosarcoma and neuroblastoma-it's not only the T cells that matter.
Arnett AB; Heczey A
Cancer Cell; 2024 Jan; 42(1):8-10. PubMed ID: 38134937
[TBL] [Abstract] [Full Text] [Related]
12. The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
Nakano K
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069146
[TBL] [Abstract] [Full Text] [Related]
13. Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.
Tian M; Wei JS; Shivaprasad N; Highfill SL; Gryder BE; Milewski D; Brown GT; Moses L; Song H; Wu JT; Azorsa P; Kumar J; Schneider D; Chou HC; Song YK; Rahmy A; Masih KE; Kim YY; Belyea B; Linardic CM; Dropulic B; Sullivan PM; Sorensen PH; Dimitrov DS; Maris JM; Mackall CL; Orentas RJ; Cheuk AT; Khan J
Cell Rep Med; 2023 Oct; 4(10):101212. PubMed ID: 37774704
[TBL] [Abstract] [Full Text] [Related]
14. ErbB2 (HER2)-car-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
Heim C; Moser LM; Kreyenberg H; Bonig HB; Tonn T; Wels WS; Gradhand E; Ullrich E; Meister MT; Koerkamp MG; Holstege FCP; Drost J; Klusmann JH; Bader P; Merker M; Rettinger E
Front Immunol; 2023; 14():1228894. PubMed ID: 37662907
[TBL] [Abstract] [Full Text] [Related]
15. Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells.
Elmarsafawi AG; Hesterberg RS; Fernandez MR; Yang C; Darville LN; Liu M; Koomen JM; Phanstiel O; Atkins R; Mullinax JE; Pilon-Thomas SA; Locke FL; Epling-Burnette PK; Cleveland JL
JCI Insight; 2023 Sep; 8(18):. PubMed ID: 37581943
[TBL] [Abstract] [Full Text] [Related]
16. Promise and Challenges of T Cell Immunotherapy for Osteosarcoma.
Park JA; Cheung NV
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569894
[TBL] [Abstract] [Full Text] [Related]
17. 4-1BB Targeting Immunotherapy: Mechanism, Antibodies, and Chimeric Antigen Receptor T.
Shen X; Zhang R; Nie X; Yang Y; Hua Y; Lü P
Cancer Biother Radiopharm; 2023 Sep; 38(7):431-444. PubMed ID: 37433196
[TBL] [Abstract] [Full Text] [Related]
18. ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma.
Mensali N; Köksal H; Joaquina S; Wernhoff P; Casey NP; Romecin P; Panisello C; Rodriguez R; Vimeux L; Juzeniene A; Myhre MR; Fåne A; Ramírez CC; Maggadottir SM; Duru AD; Georgoudaki AM; Grad I; Maturana AD; Gaudernack G; Kvalheim G; Carcaboso AM; de Alava E; Donnadieu E; Bruland ØS; Menendez P; Inderberg EM; Wälchli S
Nat Commun; 2023 Jun; 14(1):3375. PubMed ID: 37291203
[TBL] [Abstract] [Full Text] [Related]
19. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
[TBL] [Abstract] [Full Text] [Related]
20. "I just wanted to speak to someone- and there was no one…": using Burden of Treatment Theory to understand the impact of a novel ATMP on early recipients.
Litchfield I; Calvert MJ; Kinsella F; Sungum N; Aiyegbusi OL
Orphanet J Rare Dis; 2023 Apr; 18(1):86. PubMed ID: 37069697
[TBL] [Abstract] [Full Text] [Related]
[Next]
